KẾT QUẢ PHẪU THUẬT VÀ ĐÁP ỨNG HÓA TRỊ TÂN BỔ TRỢ UNG THƯ BIỂU MÔ BUỒNG TRỨNG GIAI ĐOẠN TIẾN XA

Abstract

Objectives: To evaluate surgical outcomes and response to neoadjuvant chemotherapy (NACT) in advanced-stage epithelial ovarian carcinoma and to analyze the association between these two domains. Materials and methods: A descriptive cohort of 98 patients with FIGO stage IIIC–IV ovarian cancer treated from 2019 to 2025 at Hanoi Medical University Hospital and K Hospital; all patients received NACT followed by interval debulking surgery (IDS). Results: Mean age 59.4 ± 9.0 years; 92.9% had ECOG performance status 0–1. The overall response rate was 95.9% for omental disease and 94.9% for ovarian tumors, with complete responses exceeding 44%. A Chemotherapy Response Score of 3 (CRS3) was observed in 16% of cases. R0 cytoreduction (no macroscopic residual disease) was achieved in 82.6%. Postoperative morbidity was low (bowel obstruction 1.0%, hemorrhage 3.1%). Conclusions: NACT followed by IDS is effective and safe in advanced-stage disease, yielding high R0 rates; however, the depth of histopathologic response remains limited (CRS3 16%), underscoring the persistent challenge of complete eradication of malignant cells.